The Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo ®) plus ipilimumab (Yervoy ® ), both from Bristol Myers Squibb Company, as an option for first-line therapy for ...

NAFLD is a silent liver threat affecting millions. An expert explains its link to diet, lifestyle, and rising liver cancer risk worldwide. Read on..., Health News - Times Now ...

Professor Park Joong-won of the Department of Gastroenterology at Myongji Hospital announced that the combination treatment ...